Mesenchymal stem cell

Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco

Retrieved on: 
Wednesday, January 15, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Regenerative biomedicine, Mesoblast, Mesenchymal stem cell, Cell therapy, Bone marrow, Prochymal

Commercial plans for Ryoncil were presented atthe 2020 Biotech Showcase being held this week in San Francisco, CA.

Key Points: 
  • Commercial plans for Ryoncil were presented atthe 2020 Biotech Showcase being held this week in San Francisco, CA.
  • If approved, Ryoncil is planned to be launched in the US in 2020.
  • Mesoblasts lead product candidate, Ryoncil, is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor.
  • The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates.

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

Retrieved on: 
Tuesday, January 7, 2020
Branches of biology, Biology, Life sciences, Stem cells, Developmental biology, Biotechnology, Cell biology, Mesenchymal stem cell, Cellular differentiation, Stem-cell therapy, Induced stem cells

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors.
  • The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Driven by EXOSOMES, Powered by PEPTIDES, GROWTH FACTORS, CYTOKINES, DNA REPAIR ENZYMES™

Retrieved on: 
Tuesday, November 26, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Mesenchymal stem cell

SCOTTSDALE, Ariz., Nov. 26, 2019 /PRNewswire/ --hMSCSkincare introduces powerhouse formulations featuring innovative, clinically validated ingredients utilizing humanHybrid Mesenchymal Stem Cell technology, MTP technology (Multiple Targeting Peptides), DNA Repair Enzymes, Amino Acids, & Potent Antioxidants.

Key Points: 
  • SCOTTSDALE, Ariz., Nov. 26, 2019 /PRNewswire/ --hMSCSkincare introduces powerhouse formulations featuring innovative, clinically validated ingredients utilizing humanHybrid Mesenchymal Stem Cell technology, MTP technology (Multiple Targeting Peptides), DNA Repair Enzymes, Amino Acids, & Potent Antioxidants.
  • Core hMSCtechnologywas developed after elaborate lab research, culturing methods, and blend ratios by two Ph.D biomedical scientists with expertise in stem cell research and cancer molecular biology specificallyfor use intopical skin care.
  • Each product is uniquely formulated and designed for optimal penetration while working synergistically to address skin firmness, even tone, protection, repair, and natural moisturizing factors.
  • Maximum results achieved when used as a system, can be used independently as directed.

2020 Mesenchymal Stem Cells in Human Health and Diseases - Numerous MSC-Based Studies are Ongoing Each Year, Each Offering Hope for Novel Treatments in Human Disease - ResearchAndMarkets.com

Retrieved on: 
Monday, November 25, 2019
Health, Stem cells, Branches of biology, Biology, Stem cells, Life sciences, Mesenchymal stem cell, Stem-cell therapy, Clinical uses of mesenchymal stem cells

The "Mesenchymal Stem Cells in Human Health and Diseases" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mesenchymal Stem Cells in Human Health and Diseases" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.
  • Mesenchymal Stem Cells in Human Health and Diseases provides a contemporary overview of the fast-moving field of MSC biology, regenerative medicine and therapeutics.
  • Numerous MSC-based studies are ongoing each year, each offering hope for novel treatments in human disease.
  • Mesenchymal Stem Cell Roles in Human Health and Diseases: General Discussion, Conclusion Remark and Future Direction
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191125005431/en/

Multiple Doses of Stem Cells Show Potential in Treating Severe Asthma

Retrieved on: 
Wednesday, November 20, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Developmental biology, Cell biology, Stem-cell therapy, Mesenchymal stem cell

DURHAM, N.C., Nov. 20, 2019 /PRNewswire-PRWeb/ -- A study released today in STEM CELLS Translational Medicine (SCTM) describes how multiple doses of a type of stem cell called mesenchymal stromal cells (MSCs) might offer a new way to treat people suffering from severe asthma.

Key Points: 
  • DURHAM, N.C., Nov. 20, 2019 /PRNewswire-PRWeb/ -- A study released today in STEM CELLS Translational Medicine (SCTM) describes how multiple doses of a type of stem cell called mesenchymal stromal cells (MSCs) might offer a new way to treat people suffering from severe asthma.
  • But this is the first study demonstrating that multiple doses of MSCs may induce immunosuppressive effects in experimental allergic asthma," Dr. Rocco said.
  • About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.
  • RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

Hope Biosciences Receives FDA Approval to Commence Groundbreaking Stem Cell Clinical Trial for Alzheimer’s Disease

Retrieved on: 
Wednesday, November 20, 2019
Technology, Medical devices, FDA, Genetics, Clinical trials, Stem cells, Biotechnology, Health, Data management, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Mesenchymal stem cell, Cell therapy, Stem-cell therapy

Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimers Disease, in partnership with Altoida, Inc., a predictive digital biomarker company.

Key Points: 
  • Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimers Disease, in partnership with Altoida, Inc., a predictive digital biomarker company.
  • We expect HB-adMSCs to safely and effectively diminish the effects of Alzheimers Disease and provide patients more time with better cognitive function.
  • As a high-tech cell therapy manufacturer, Hope Biosciences seeks out innovative, novel tools to assemble comprehensive clinical protocols that deliver superior cell products with state-of-the-art assessment technology.
  • Hope Biosciences is actively offering clinical grade, stem cell banking for adults and newborns.

BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update

Retrieved on: 
Thursday, November 14, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Draft:BrainStorm Cell Therapeutics, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update

Retrieved on: 
Tuesday, November 5, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Induced stem cells, Cell biology, Mesenchymal stem cell, Adult stem cell, Cellular differentiation, Draft:BrainStorm Cell Therapeutics

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Retrieved on: 
Friday, October 25, 2019
Branches of biology, Biology, Life sciences, Stem cells, Developmental biology, Biotechnology, Mesenchymal stem cell, Cell biology, Cellular differentiation

Chaim Lebovits, President and CEO of BrainStorm said, We are pleased to have the opportunity to have Dr. Shah present at the Dawson James Small Cap Growth Conference.

Key Points: 
  • Chaim Lebovits, President and CEO of BrainStorm said, We are pleased to have the opportunity to have Dr. Shah present at the Dawson James Small Cap Growth Conference.
  • Dr. Shah, joined BrainStorm in September 2019, and we look forward to having him present the Companys growth strategy and future to a wide audience of accreditied investors.
  • NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019

Retrieved on: 
Thursday, October 24, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Mesenchymal stem cell, Draft:BrainStorm Cell Therapeutics, Stem-cell therapy

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK .Cell Series UK, will be held October 29-30, 2019, at London Novotel West, London, UK.

Key Points: 
  • NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK .Cell Series UK, will be held October 29-30, 2019, at London Novotel West, London, UK.
  • Mr. Lebovits Keynote Address, Stem Cell Therapeutic Approaches For ALS, will be presented to leading members of the scientific and business community including potential partners and investors.
  • NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.